Bibliographic Details
| Title: |
Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD |
| Authors: |
Caramori G, Chung KF, Adcock IM |
| Source: |
International Journal of COPD, Vol 2014, Iss default, Pp 249-256 (2014) |
| Publisher Information: |
Dove Medical Press, 2014. |
| Publication Year: |
2014 |
| Collection: |
LCC:Diseases of the respiratory system |
| Subject Terms: |
Diseases of the respiratory system, RC705-779 |
| More Details: |
Gaetano Caramori,1 Kian Fan Chung,2 Ian M Adcock2 1Centro Interdipartimentale per lo Studio delle Malattie Infiammatorie delle Vie Aeree e Patologie Fumo-correlate (CEMICEF; formerly Centro di Ricerca su Asma e BPCO), Sezione di Medicina Interna e Cardiorespiratoria, Università di Ferrara, Ferrara, Italy; 2Airways Disease Section, National Heart and Lung Institute, Royal Brompton Hospital Biomedical Research Unit, Imperial College London, London, UK Abstract: Currently, there is no cure for chronic obstructive pulmonary disease (COPD). The limited efficacy of current therapies for COPD indicates a pressing need to develop new treatments to prevent the progression of the disease, which consumes a significant amount of health care resources and is an important cause of mortality worldwide. Current national and international guidelines for the management of stable COPD patients recommend the use of inhaled long-acting bronchodilators, inhaled corticosteroids, and their combination for maintenance treatment of moderate to severe stable COPD. Once-daily fluticasone furoate/vilanterol dry powder inhaler combination therapy has recently been approved by the US Food and Drug Administration and the European Medicines Agency as a new regular treatment for patients with stable COPD. Fluticasone furoate/vilanterol dry powder inhaler combination therapy has been shown to be effective in many controlled clinical trials involving thousands of patients in the regular treatment of stable COPD. This is the first once-daily combination of ultra-long-acting inhaled ß2-agonists and inhaled glucocorticoids that is available for the treatment of stable COPD and has great potential to improve compliance to long-term regular inhaled therapy and hence to improve the natural history and prognosis of COPD patients. Keywords: COPD, LABA, ULABA, ICS, bronchodilator, new drugs |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1178-2005 |
| Relation: |
http://www.dovepress.com/profile-of-fluticasone-furoatevilanterol-dry-powder-inhaler-combinatio-a15930; https://doaj.org/toc/1178-2005 |
| Access URL: |
https://doaj.org/article/68bd78484d7f4cb7a6ff8dcd5d92ac9a |
| Accession Number: |
edsdoj.68bd78484d7f4cb7a6ff8dcd5d92ac9a |
| Database: |
Directory of Open Access Journals |
